Table 1. Correlation of BV6 treatment sensitivity with clinical, cytogenetic and molecular marker distribution.
| BV6-sensitive | BV6-resistant | P-value | ||
|---|---|---|---|---|
| n = 34 | n = 19 | Pearson chi2 | Mann-Whitney U | |
| Age | 52 (21–77) | 57 (20–76) | 0.9484 | |
| Sex: | ||||
| Male | 15/31 | 11/18 | 0.3896 | |
| Female | 6/31 | 7/18 | ||
| Karyotype: | ||||
| normal | 18/30 | 7/16 | 0.2920 | |
| CBF | 5/30 | 3/16 | 0.8591 | |
| t(15;17) | 1/30 | 0/15 | 0.4745 | |
| complex | 1/30 | 2/16 | 0.2304 | |
| other | 6/30 | 4/16 | 0.6954 | |
| Molecular markers: | ||||
| FLT3 ITD MUT | 14/31 | 4/15 | 0.1141 | |
| FLT3 TKD MUT | 4/31 | 0/15 | 0.1454 | |
| CEBPA MUT | 0/20 | 2/9 | 0.0144* | |
| NPM1 MUT | 18/31 | 3/15 | 0.0076** | |
Data on clinical, cytogenetic and molecular markers were available for 31/34 BV6-sensitive and 18/19 BV6-resistant cases.